Dorsomorphin 2HCl
别名: BML-275 2HCl,Compound C 2HCl
Dorsomorphin 2HCl是一种有效的，可逆的，选择性AMPK抑制剂，在无细胞试验中Ki为109 nM，对一些结构相关的激酶，包括ZAPK， SYK， PKCθ，PKA和JAK3没有显著的抑制作用。也会抑制I型BMP受体。Dorsomorphin 可诱导癌细胞系的自噬。
Dorsomorphin 2HCl Chemical Structure
CAS: 1219168-18-9
产品质控
批次：
纯度：
99.98%
99.98
Dorsomorphin 2HCl相关产品
相关信号通路图
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| HepG2 | Function assay | 10 uM | 30 mins | Inhibition of BMPR1-mediated hepcidin mRNA expression in BMP2-stimulated human HepG2 cells at 10 uM treated 30 mins before BMP2 challenge measured after 16 hrs by qRT-PCR analysis | 18026094 |
| Hep3B | Function assay | 10 uM | 30 mins | Inhibition of BMPR1-mediated hepcidin mRNA expression in IL6-stimulated human Hep3B cells at 10 uM treated 30 mins before IL6 challenge measured after 6 hrs by qRT-PCR analysis | 18026094 |
| Hep3B | Function assay | 10 uM | 30 mins | Inhibition of BMPR1-mediated Id1 mRNA expression in IL6-stimulated human Hep3B cells at 10 uM treated 30 mins before IL6 challenge measured after 6 hrs by qRT-PCR analysis | 18026094 |
| C2C12 | Function assay | 4 uM | Inhibition of BMPR1-mediated osteoblast differentiation in BMP4-stimulated mouse C2C12 cells assessed as decrease in alkaline phosphatase level at 4 uM by spectrophotometry | 18026094 | |
| C2C12 | Function assay | 4 uM | Inhibition of BMPR1-mediated osteoblast differentiation in BMP6-stimulated mouse C2C12 cells assessed as decrease in alkaline phosphatase level at 4 uM by spectrophotometry | 18026094 | |
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | ||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | ||
| Rh30 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | ||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | ||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | ||
| KB-3-1 | qHTS assay | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 31515284 | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | Dorsomorphin 2HCl是一种有效的，可逆的，选择性AMPK抑制剂，在无细胞试验中Ki为109 nM，对一些结构相关的激酶，包括ZAPK， SYK， PKCθ，PKA和JAK3没有显著的抑制作用。也会抑制I型BMP受体。Dorsomorphin 可诱导癌细胞系的自噬。 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | Dorsomorphin抑制AICAR或者二甲双胍引起的ACC失活，也会减弱肝细胞中AICAR和二甲双胍增加脂肪酸氧化或抑制脂肪生成基因的作用。[1] Dorsomorphin对AMPK活性的抑制几乎完全抑制了HT-29细胞中的自体吞噬的蛋白质水解作用。[2] 此外，Dorsomorphin选择性抑制BMP I型受体ALK2，ALK3和ALK6，并因此阻断BMP介导的SMAD1/5/8磷酸化作用，靶点基因转录和成骨分化。[3] |
|||
|---|---|---|---|---|
| 实验图片 | 检测方法 | 检测指标 | 实验图片 | PMID |
| Western blot | p-SMAD / SMAD Id1 / Id2 / Id3 pAMPK / AMPK / pACC / ACC / pRaptor / HIF1α p-ERK / ERK / Bcl2 / BAX / Cleaved caspase-3 LC3B I/ LC3B II |
|
30808965 | |
| Immunofluorescence | MyHC Id1 / MyoD |
|
20689554 | |
| Growth inhibition assay | Cell viability (MM cells) Cell viability (glioma cell lines) |
|
25010525 | |
| 体内研究(In Vivo) | ||
| 体内研究活性 | 在成年小鼠体内，Dorsomorphin (10 毫克/千克)降低肝杀菌肽表达的基础水平，并增加血清中铁离子浓度。[3] Dorsomorphin (0.2 毫克/千克，静脉注射)显著减少LPS 处理的大鼠胸主动脉中VCAM-1 和 ICAM-1的表达。[4] |
|
|---|---|---|
| 动物实验 | Animal Models | Iron-replete 小鼠 |
| Dosages | ~10 毫克/千克 | |
| Administration | 静脉注射 | |
化学信息&溶解度
| 分子量 | 472.41 | 分子式 | C24H25N5O.2HCl |
| CAS号 | 1219168-18-9 | SDF | Download Dorsomorphin 2HCl SDF |
| Smiles | C1CCN(CC1)CCOC2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC=C5)N=C3.Cl.Cl | ||
| 储存条件(自收到货起) | |||
|
体外溶解度 |
Water : 47 mg/mL (99.48 mM) DMSO : Insoluble ( ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Ethanol : Insoluble |
摩尔浓度计算器 |
|
体内溶解配方 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | |||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
常见问题及建议解决方法
问题 1:
Is there any information you may provide as to WHICH AMPK SUBUNIT is this drug targeting in the AMPK complex?
回答：
According to the reference （see link below), Dorsomorphin(Compound C) should target the AMPK alpha subunit through ALCAR or metformin. http://www.ncbi.nlm.nih.gov/pubmed/20844250
Tags: buy Dorsomorphin 2HCl | Dorsomorphin 2HCl supplier | purchase Dorsomorphin 2HCl | Dorsomorphin 2HCl cost | Dorsomorphin 2HCl manufacturer | order Dorsomorphin 2HCl | Dorsomorphin 2HCl distributor
